University System of Maryland

Other

Johns Hopkins University

Nabi

Universy of Maryland

Ramachandra S Hosmane

Enrico Bucci

Venu Raman

Ramesh K Sood

Raj Kumar

Paddada R Rao

Barry Burns

Clara Fronticelli-Bucci

The invention encompasses novel compounds and pharmaceutically acceptable salts thereof and compositions including therapeutically or prophylactically effective amounts of such compounds or pharmaceutically acceptable salts thereof. The invention also encompasses methods for treating or preventing diseases and disorders associated abnormal cell growth, for example, treating or preventing cancer or tumor growth, which methods include administering to a mammal in need thereof a composition comprising a therapeutically or prophylactically effective amount of a compound of the invention or a pharmaceutically acceptable salt thereof.

Fused diimidazodiazepine compounds and methods of use and manufacture thereof

The present invention relates to compositions comprising analogues of purine nucleosides containing a ring-expanded (&ldquo;fat&rdquo;) heterocyclic ring, in place of purine, and an unmodified or modified sugar residue, pharmaceutically acceptable derivatives of such compositions, as well as methods of use thereof. In particular, these compositions may be utilized in the treatment of certain cancers, bacterial, fungal, parasitic, and viral infections, including, but not limited to, Acquired Immunodeficiency Syndrome (AIDS), hepatitis, Epstein-Barr and cytomegalovirus.

Ring-expanded nucleosides and nucleotides

The present invention relates to compositions comprising analogues of purine nucleosides containing a ring-expanded ('fat') heterocyclic ring, in place of purine, and an unmodified or modified sugar residue, pharmaceutically acceptable derivatives of such compositions, as well as methods of use thereof. In particular, these compositions may be utilized in the treatment of certain cancers, bacterial, fungal, parasitic, and viral infections, including, but not limited to, Acquired Immunodeficiency Syndrome (AIDS) and hepatitis.

The present invention provides a salicylate analogue having the structure ##STR1## wherein R is selected from the group consisting of hydrogen, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl; pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, phenyl, naphthyl and cyclohexyl; wherein R1 is selected from the group consisting of hydrogen, a C1-C12 alkyl group, F, Cl, Br, I, CO.sub.2 H, CONHR, CONR.sub.2, CO.sub.2 R, C.tbd.N, CHO, COR, SO.sub.3, SO.sub.2 NHR, SO.sub.2 NR.sub.2, OH, OR, OCOR, SH, SR, OCONHR, OCONR.sub.2, SCOR, SCONHR, SCONR.sub.2 and NH2, NHR, NHCOR and NR2; and wherein R1 is in the 3-, 4-, 5- or 6-position, or a combination thereof. Also provided are various pharmaceutical compositions of the novel compounds of the present invention.

Analogues of acetylsalicylic acid and novel uses thereof

Stroma-free hemoglobin cross-linked with reagents that mimic 2,3 diphosphoglycerate and transform stroma-free hemoglobin into a physiologically competent oxygen carrier which is retained in vivo for adequate periods of time and thus can be used in fluids for transporting oxygen; reagents for cross-linking stroma-free hemoglobin and method for cross-linking stroma-free hemoglobin.

Growing community of inventors

Columbia, MD, United States of America

Ramachandra S Hosmane